Intercure (INCR) AI Stock Analysis

• Market Cap: 251.36M
• Dividend Yield: N/A
• Average Volume (3M): 79.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IL
• Employees: 320
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -3.60
• Shares Outstanding: 54,512,608
• 10 Day Avg. Volume: 76,791
• 30 Day Avg. Volume: 79,789
• PEG Ratio: -0.43
• Price to Book (P/B): 0.65
• Price to Sales (P/S): 1.09
• P/FCF Ratio: -3.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: 444.00 ▼(-13.65% Downside)

Intercure's overall stock score is primarily impacted by its financial challenges, including declining revenues and negative cash flow. Technical analysis further indicates bearish momentum, contributing to a lower score. The absence of valuation metrics adds uncertainty, resulting in a neutral valuation score.

Intercure Business Overview & Revenue Model

Company Description

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

How the Company Makes Money

Intercure generates revenue through multiple streams, primarily from the sale of medical cannabis products to patients and healthcare providers. The company's revenue model is bolstered by direct sales through its dispensaries and online platforms, facilitating access for patients in need of medical cannabis. Additionally, Intercure benefits from partnerships with healthcare institutions and other stakeholders in the medical community, enhancing its market presence and credibility. The company may also explore opportunities for licensing its products or technologies, further diversifying its income sources. Key factors contributing to its earnings include regulatory approvals for its product lines, the expansion of its distribution network, and increasing consumer demand for medical cannabis alternatives.

Intercure Financial Statement Overview

Summary

Intercure is facing financial challenges with declining revenues, negative profitability, and cash flow issues. While the balance sheet shows manageable leverage, the decreasing equity and cash flow difficulties could hinder future growth and stability.

Income Statement

Intercure has experienced a significant decline in revenue and profitability over the reported periods. The gross profit margin decreased, and the company reported negative EBIT and EBITDA margins, indicating operational challenges. Net profit margin is also negative, reflecting ongoing losses.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, showing some leverage but not excessively high. However, the stockholders' equity has been decreasing, which could be concerning. The equity ratio suggests a fair level of equity financing, but declining equity may pose future risks.

Cash Flow

Intercure's cash flow statement highlights negative free cash flow and operating cash flow, indicating cash flow difficulties. The company also struggles with generating positive cash flow relative to net income, suggesting inefficiencies in cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	238.84M	355.55M	388.68M	219.68M	65.03M
Gross Profit	30.23M	105.09M	155.08M	91.13M	31.98M
EBITDA	-51.31M	-23.90M	70.23M	31.17M	-34.53M
Net Income	-67.80M	-61.96M	44.82M	4.69M	-37.23M
Balance Sheet
Total Assets	762.57M	786.61M	958.01M	686.32M	326.27M
Cash, Cash Equivalents and Short-Term Investments	78.65M	101.33M	232.79M	196.55M	38.26M
Total Debt	211.40M	195.68M	255.16M	108.91M	6.68M
Total Liabilities	364.90M	329.55M	436.53M	227.13M	34.16M
Stockholders Equity	396.97M	455.11M	501.31M	448.03M	274.51M
Cash Flow
Free Cash Flow	-71.30M	-56.25M	31.52M	10.99M	-13.04M
Operating Cash Flow	-66.93M	-53.63M	51.27M	25.02M	7.80M
Investing Cash Flow	17.69M	4.77M	-142.50M	-65.21M	-22.76M
Financing Cash Flow	26.45M	-82.89M	120.45M	197.94M	25.29M

Intercure Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 514.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:INCR, the sentiment is Negative. The current price of 514.2 is above the 20-day moving average (MA) of 499.26, below the 50-day MA of 523.22, and below the 200-day MA of 545.38, indicating a bearish trend. The MACD of -18.53 indicates Positive momentum. The RSI at 30.51 is Neutral, neither overbought nor oversold. The STOCH value of 19.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:INCR.

Intercure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INCR	44 Neutral	251.36M	―	―	―	―	―

Intercure Corporate Events

InterCure and Cannasoul Forge Strategic Partnership to Innovate Cannabis Therapeutics

On November 3, 2025, InterCure Ltd. announced a strategic partnership with Cannasoul R&D Ltd., a leader in cannabis research. The agreements include a Share Purchase Agreement granting InterCure a 28% stake in Cannasoul, with potential to increase to 51%, and a Collaboration Agreement to advance cannabis therapeutics. This collaboration positions InterCure to capitalize on potential regulatory changes in the U.S. cannabis market, enhancing its scientific leadership and expanding its international footprint.

The most recent analyst rating on (IL:INCR) stock is a Hold with a ILs499.00 price target. To see the full list of analyst forecasts on Intercure stock, see the IL:INCR Stock Forecast page.

InterCure Announces Strong First Half 2025 Results Amid Strategic Expansion

InterCure Ltd. reported its financial results for the first half of 2025, highlighting NIS 130 million in revenue and NIS 12 million in positive operating cash flow, marking its eleventh consecutive half of positive Adjusted EBITDA. Despite challenges such as the October 7 attack and ongoing war in Gaza, the company resumed production and launched over 40 new SKUs. InterCure is strategically expanding its international presence, notably through the acquisition of Botanico Ltd. (ISHI), which enhances its access to premium U.S. genetics and cultivation technologies. The company is also monitoring U.S. regulatory changes, positioning itself to capitalize on potential cannabis rescheduling.

The most recent analyst rating on (IL:INCR) stock is a Hold with a ILs548.00 price target. To see the full list of analyst forecasts on Intercure stock, see the IL:INCR Stock Forecast page.

InterCure Acquires ISHI to Expand U.S. Cannabis Market Reach

InterCure Ltd. announced the strategic acquisition of Botanico Ltd., also known as ISHI, on September 17, 2025. This acquisition, expected to close in Q1 2026, marks a significant milestone in InterCure’s global expansion strategy by providing access to premium U.S. cannabis technology and brands. The transaction involves acquiring 100% of ISHI in two phases, with the initial phase involving the purchase of 50% of ISHI’s shares. This move positions InterCure to capitalize on potential regulatory changes in the U.S. cannabis market, particularly the rescheduling of cannabis, which could open new opportunities for international operators. The acquisition also strengthens InterCure’s management team with the inclusion of ISHI’s founders and enhances its supply chain and distribution operations.

The most recent analyst rating on (IL:INCR) stock is a Hold with a ILs548.00 price target. To see the full list of analyst forecasts on Intercure stock, see the IL:INCR Stock Forecast page.